Here are some considerations: Thyroid and Endocrine Health: If you or your family have a history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome types 2, its vital to discuss these conditions with your doctor, as tirzepatide may not be appropriate
Furthermore, while the majority of clinical trial designs have reasonable endpoints, there are also non-inferiority analyses like SURPASS-AP-Combo.Studies have shown that tirzepatide excels in improving glycemic control and promoting weight loss
Body aches (myalgia): About 5% of users report muscle aches, with fatigue commonly noted during weeks 12 of treatment
Seeking subtle and sustained benefits Mounjaro promotes significant blood sugar control, and Zepbound reduces body weight
This article reviews current FDA guidance, sourcing requirements, and safety considerations related to compounded tirzepatide in 2026